SNS Financial Group’s Actinium Pharmaceuticals ATNM Stock Holding History

SNS Financial Group’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.1K	Buy	+43,000	New	+$49.7K	﹤0.01%	548
2020 Q1	–	Sell	-1,167	Closed	-$8K	–	198
2019 Q4	$8K	Hold	1,167	–	–	﹤0.01%	223
2019 Q3	$8K	Hold	1,167	–	–	﹤0.01%	203
2019 Q2	$9K	Buy	1,167 +300	+35%	+$3.01K	﹤0.01%	211
2019 Q1	$12K	Hold	867	–	–	﹤0.01%	190
2018 Q4	$10K	Hold	867	–	–	﹤0.01%	193
2018 Q3	$19K	Hold	867	–	–	﹤0.01%	178
2018 Q2	$17K	Hold	867	–	–	﹤0.01%	172
2018 Q1	$9K	Buy	867 +200	+30%	+$3.4K	﹤0.01%	166
2017 Q4	$13K	Buy	667 +67	+11%	+$1.35K	﹤0.01%	174
2017 Q3	$10K	Buy	600 +200	+50%	+$4.39K	﹤0.01%	168
2017 Q2	$15K	Buy	400 +67	+20%	+$2.8K	﹤0.01%	163
2017 Q1	$15K	Buy	+333	New	+$12.8K	﹤0.01%	200

Other funds holding ATNM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CFM

Compass Financial Management Tampa, Florida $829M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SNS Financial Group's ATNM Position: Q2 2026 in Review

SNS Financial Group opened a new position in Actinium Pharmaceuticals (ATNM) in Q2 2026: 43,000 shares worth $42.1K. The stake represents ﹤0.01% of the portfolio and ranks #548 among its holdings. This is a return to the name: SNS Financial Group previously reported a position in ATNM as recently as Q4 2019.

SNS Financial Group first reported a position in ATNM in Q1 2017 and has held it in 13 quarters since. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

SNS Financial Group held 43,000 shares of Actinium Pharmaceuticals worth $42.1K as of Q2 2026.
Actinium Pharmaceuticals was a new SNS Financial Group position in Q2 2026.
Actinium Pharmaceuticals made up ﹤0.01% of SNS Financial Group's portfolio in Q2 2026, its #548 holding.
SNS Financial Group first reported a position in Actinium Pharmaceuticals in Q1 2017 and has held it in 13 quarters since.
47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on SNS Financial Group's 13F filing for Q2 2026, filed 11 Aug 2026.